Trastuzumab for gastric cancer treatment - Authors' reply

The Lancet

Volumn 376, Issue 9754, 2010, Pages 1736-1737

  Munro, Alastair J ^a   Niblock, Paddy G ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; ESOPHAGUS CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; POST HOC ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; STOMACH CANCER;

EID: 85101896539     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62128-9     Document Type: Letter

References (4)

1. Y-J Bang, E Van Cutsem, A Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
2. National Institute for Clinical Excellence Guidance on the use of trastuzumab for the treatment of advanced breast cancer 2002 National Institute for Clinical Excellence London http://guidance.nice.org.uk/TA34 (accessed Oct 6, 2010).
3. DJ Slamon, B Leyland-Jones, S Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
4. Second International Study of Infarct Survival Collaborative Group (ISIS) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 332 1988 349 360